Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers - Additional Information (Detail)

v3.10.0.1
Revenues from Contracts and Significant Customers - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
May 11, 2015
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2017
Revenue Recognition Milestone Method Payments Due         $ 500,000    
License and Services Revenue   $ 100,000     500,000    
Return Reserve   $ 700,000   $ 300,000 700,000   $ 300,000
Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]              
Revenue Recognition, Milestone Method, Revenue Recognized     $ 100,000 100,000 400,000   600,000
Payment Of Upfront Licensing Fee         $ 1,000,000    
Research And Development Cost Shared Percentage   50.00%     50.00%    
Checkpoint Collaboration Agreement with TGTX NeuPharma, Inc. and TGTX [Member]              
Revenue Recognition, Milestone Method, Revenue Recognized   $ 0   200,000 $ 31,000   400,000
Customer One [Member]              
Sales Revenue, Goods, Gross   11,500,000   4,200,000 11,500,000   5,300,000
Accounts Receivable, Net   3,900,000   2,100,000 3,900,000   2,100,000
Customer Two [Member]              
Sales Revenue, Goods, Gross   2,400,000   2,200,000 6,900,000   3,800,000
Accounts Receivable, Net   1,000,000   $ 700,000 1,000,000   $ 700,000
Customer Three [Member]              
Sales Revenue, Goods, Gross         5,100,000    
First Commercial Sale Milestone [Member] | Checkpoint Therapeutics, Inc [Member]              
Revenue Recognition Milestone Method Payments Due         21,500,000    
Additional Sales Milestone [Member] | Checkpoint Therapeutics, Inc [Member]              
Revenue Recognition Milestone Method Payments Due         60,000,000    
Clinical Development Milestone [Member] | Checkpoint Therapeutics, Inc [Member]              
Revenue Recognition Milestone Method Payments Due   0     7,000,000 $ 0  
Commercial Sales In Specified Territories [Member] | Checkpoint Therapeutics, Inc [Member]              
Revenue Recognition Milestone Method Payments Due         14,500,000    
Successful Achievement Of One Preclinical Milestone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]              
Revenue Recognition Milestone Method Payments Due         25,500,000    
Clinical Development And Regulatory Milestones [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]              
Revenue Recognition Milestone Method Payments Due         87,200,000    
Five Regulatory Approvals And First Commercial Sales [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]              
Maximum Potential Milestone Payments   61,700,000     61,700,000    
Sale Millstone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]              
Maximum Potential Milestone Payments   $ 89,000,000     $ 89,000,000    
Dana Farber Cancer Institute [Member]              
Proceeds from issuance of Common stock $ 10,000,000